The Utility of ODM-201 in CRPC

February 13, 2014
Neal D. Shore, MD, FACS

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).

Clinical Pearls

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).

  • In phase I and II multinational trials, favorable results have been observed regarding PSA kinetics modulation
  • The organic structure of ODM-201 seems to cause the agent to have a much lower penetration through the blood-brain barrier
  • The efficacy of ODM-201 is being measured in terms of its impact on radiographic disease, PSA, and the androgen receptor
  • ODM-201 has been studied in patients prior to and following chemotherapy, as well as in patients who have and have not received abiraterone
  • Additional trials are being planned to analyze safety, efficacy, and tolerability
  • ODM-201 will be studied in a large trial of non-metastatic patients